Shandong Sino Pharmaceutical Technology Co., Ltd.

We are supplying all of our  foreign customers with Customized Pharmaceutical Formulations or Dosage Forms.

You can tell us any pharmaceutical product, no matter what it is that you want. And then we will give you a detailed solution as per your requirement.  

Tesamorelin (trade name Egrifta SV/WR) is an FDA-approved 44-amino acid synthetic growth hormone-releasing hormone (GHRH) analogue, mainly used for the treatment of visceral obesity caused by HIV-related lipodystrophy It works by stimulating the pituitary gland to release endogenous growth hormone (GH) and insulin-like growth factor-1 (IGF-1), and is administered subcutaneously with controllable safety.


Clinical application and administration regimens
1.Approved indications and therapeutic effects

Core indication: Excessive visceral fat (VAT) in HIV-related lipodystrophy. It can significantly reduce abdominal visceral fat (with an average reduction of about 15% to 20% after 26 weeks of treatment), and has no significant effect on body weight.
Research directions: Metabolic syndrome, sarcopenia, anti-aging (improving skin elasticity and blood lipids), sleep quality regulation, etc


2.Standard dosing regimen
Dosage form, dosage, administration route, frequency, injection site, monitoring indicators
Egrifta SV 2mg subcutaneous injection once daily abdominal (rotating) GH/IGF-1, blood glucose, blood lipid, pituitary function
Egrifta WR 1.4mg per dose, subcutaneous injection once daily, abdominal injection as above, more convenient administration design


Iii. Safety and Precautions
Common adverse reactions (incidence rate > 5%)

Local: Redness, swelling, pain and itching at the injection site;
General symptoms: joint pain, muscle pain, headache, fatigue, edema, and hyperglycemia (mostly mild).

3. Contraindications and Use with caution

Contraindications: Pregnancy (Class X), pituitary tumor/hypopituitarism, allergy to ingredients, uncontrolled diabetes/hypertension;
Use with caution: Those with a history of breast/prostate cancer, abnormal thyroid function, or impaired liver or kidney function

4.Drug interactions

Avoid combination with GH, IGF-1, insulin and glucocorticoids, which may affect the blood glucose/hormone balance.
When used in combination with hypoglycemic drugs, blood sugar levels should be monitored and the dosage adjusted if necessary.